IMPORTANCE Although prospective randomized data are available to guide the multidisciplinary management of soft tissue sarcoma (STS) of the extremities, controversy exists regarding adjuvant chemotherapy and radiation therapy. 
T he contemporary management of soft tissue sarcoma (STS) of the extremities requires coordinated multimodality treatment strategies involving several specialties in a multidisciplinary setting. For localized disease, surgical resection is the cornerstone of curative-intent therapy and, with the addition of radiation therapy, has been crucial in establishing limb-sparing surgery as the standard of care. This approach was validated in seminal randomized trials demonstrating equivalent survival outcomes between amputation and conservative limb-sparing surgery combined with radiation therapy. 1, 2 Although the magnitude of the benefit of adjuvant systemic chemotherapy for localized STS is modest, statistically significant improvements in disease-free and overall survival have been shown in some randomized phase III trials. 3, 4 The Sarcoma Meta-analysis Collaboration 5 demonstrated an improvement in overall recurrence-free survival and a trend toward improved overall survival from pooled data. These findings were most notable for patients with STS of the extremities. Moreover, a more recent meta-analysis 6 demonstrated improvement in overall survival when doxorubicin hydrochloride was used in combination with ifosfamide. Despite the availability of data from randomized trials, variation in the multimodality treatment of patients with STS of the extremities exists. Although patient-specific factors have been identified that contribute to the variation in treatment and outcome, physician-specific factors have not been well studied. Martinez et al 7 showed that African American patients with STS of the extremities receive lower rates of adjuvant radiation therapy and experience worse disease-specific survival than do white patients. Similarly, low socioeconomic status is associated with poorer overall survival for patients with STS. 8 Recently, our group showed that physician experience influences treatment sequencing in STS. 9 The objective for our study was to assess the influence of physician specialty in the management of patients with STS of the extremities. We hypothesized that clinical specialty leads to bias in recommendations for adjuvant radiation therapy and systemic chemotherapy among patients undergoing curativeintent surgery for STS of the extremities. As secondary objectives, we sought to explore patient-and tumor-specific factors influencing physician recommendations for radiation therapy and chemotherapy, as well as the specialty-specific perceived benefits of these treatments.
Methods

Study Design and Survey Instrument
We conducted our study using survey methods. The survey was developed by 2 of the authors (N.W. and R.J.C.) following a literature review and a small focus group discussion. Pilot testing of the survey was performed internally at the University of California at Davis Medical Center in Sacramento for face and content validity to develop the final construct of 16 questions. Commercially available software (QuestionPro) was used for digitization and electronic dissemination via the World Wide Web in November 2009, as has been discussed previously. 10 A cover paragraph explaining the purpose of our study accompanied the survey, and a reminder was sent to participants who did not respond to the initial request. No incentive was provided to complete the survey.
The complete survey questionnaire is provided in Table 1 . The initial set of questions was structured to identify physician specialty. Subsequent modules addressed utilization of radiation therapy or systemic chemotherapy in the management of localized STS amenable to treatment with curative intent. Patient-and tumor-specific factors influencing the use of either radiation therapy or chemotherapy were queried. We did not specifically inquire about brachytherapy or intraoperative radiation therapy because these techniques are not widely available, even among academic, tertiary referral centers.
Study Population
A pool of potential respondents was identified from the database of active members of the American Society of Clinical Oncology, the Society of Surgical Oncology, and the Connective Tissue Oncology Society. Only physicians with a selfdeclared subspecialty interest in STS were chosen. No unique information that could potentially identify a respondent was collected, and all data were deidentified. Approval for our study was obtained from the institutional review board at the University of California at Davis. Completion of the survey was considered as implied consent for participation.
Statistical Analysis
Questions were scored on a 5-point Likert scale. For each question, mean values were calculated to generate a single response score. Mean values were compared using independent samples 1-way analysis of variance. The data were analyzed for homogeneity of variances, and the appropriate corrections were used for post hoc analysis. The significance level was set at P < .05 and adjusted as appropriate for multiple comparisons. For purposes of analyses, respondents were divided into groups by specialty. All tests were 2-tailed. Significance levels were set at P < .05, and confidence intervals at 95%. Statistical analysis was performed using SPSS version 16.0 statistical software (SPSS Inc).
Results
Demographics
The questionnaire was sent to 490 potential respondents and completed by 320 (65%). Data on the breakdown by specialty, by years in practice, and by percentage of clinical practice devoted to sarcoma care are outlined in Table 2 . For specialty, "others" consisted primarily of pediatric hematologists/ oncologists and pathologists. 
Role of Radiation Therapy in Management of STS
Factors Influencing Use of Radiation Therapy
The variables most likely to influence a treatment recommendation in favor of radiation therapy were the presence of margins positive for tumor ( 
Variation in Responses to Use of Radiation Therapy
Interspecialty variation was observed in responses for all variables except for margins positive for tumor (Table 3 ). In par- 
Influence of Years in Practice and Percentage of Clinical Practice Devoted to Sarcoma Care on Use of Radiation Therapy
We stratified respondents by years of practice (<5, 5-15, and >15 years) and percentage of clinical practice devoted to sarcoma care (<25%, 25%-75%, and >75%) to assess the effect of experience on factors influencing the use of radiation therapy. In all of the variables listed in Table 3 , no significant difference in aggregate response was seen for respondents when considering percentage of clinical practice (<25%, 25%-75%, and >75%) independent of specialty. For years of practice, those respondents who had been in practice for 5 to 15 years were more likely to recommend radiation therapy for tumors larger than 10 cm than were those in practice for more than 15 years ( Figure 2B ).
Factors Influencing Use of Chemotherapy in Treatment
No single variable was rated as greater than 4.0 in the recommendation to utilize systemic chemotherapy. 
Comment
Although data are available from randomized controlled trials to guide treatment decisions in the multidisciplinary management of STS of the extremities, there is a lack of consensus regarding relative indications for the use of adjuvant radiation therapy and systemic chemotherapy. By studying specialtyspecific responses to scenarios on the use of radiation therapy and systemic chemotherapy in the treatment of localized STS, we show that physician specialty is an important factor contributing to variability in treatment recommendations. The importance of radiation therapy in the management of STS of the extremities was rated highest by radiation oncologists, who were also more likely to assert that radiation therapy is underutilized in the multimodality treatment of patients with STS. Similarly, among all the responding physicians, medical oncologists assigned the greatest importance to systemic chemotherapy, even though, overall, most respondents felt that current utilization was appropriate.
Considerable interspecialty variation was observed with regard to indications for treatment, which suggests that, even among experts, there is a diversity of opinions regarding the multidisciplinary management of STS of the extremities. In general, clinicians' recommendations tend to be biased in favor of their specialty-specific modality. Although this may seem intuitive, it has not been well studied in the medical literature, in general, or in the sarcoma literature, in particular. Given the preponderance of treatment guidelines and tumor board recommendations that are based on expert opinion rather than level I evidence for a rare disease process such as STS of the extremities, it would seem to be important to deconstruct the process by which clinicians at the individual and group level arrive at treatment recommendations.
Current National Comprehensive Cancer Network guidelines recommend consideration of adjuvant radiation therapy for patients with high-grade STS, with large tumors, or with final margins close to or positive for tumors.
11 Our respondents demonstrated the highest agreement across all specialties in cases of STS of the extremities with margins positive for tumor, with a high-grade tumor, with a tumor size of greater than 10 cm, or with a tumor close to a neurovascular bundle. Although respondents rated improvement in local control as a significant benefit of radiation therapy, improvement in overall survival was not. These responses are consistent with the published literature regarding the oncologic benefits of adjuvant radiation therapy. 12 However, subtle but important differences emerged when we analyzed the responses by physician specialty. Radiation oncologists were more likely to offer radiation therapy to patients younger than 50 years of age and for tumors 5 to 10 cm in maximal size. Furthermore, they were more inclined to disagree with the statements that radiation therapy is not indicated for radiation-associated STS of the extremities and that radiation therapy is not indicated for low-grade STS of the extremities. These are controversial areas in which specific evidence-based data and guidelines are not available and for which clinicians may have substantially different views of the riskbenefit ratio of treatment. 13, 14 Overall, respondents viewed chemotherapy as less important than radiation therapy in the multidisciplinary management of STS of the extremities. This appropriately reflects the conflicting nature of data from randomized trials examining the benefits of adjuvant chemotherapy in STS of the extremities. Interestingly, both radiation and surgical oncologists placed less emphasis on a survival benefit with chemotherapy than did medical oncologists and orthopedic oncologists. Medical oncologists felt that chemotherapy played a greater role in local control than did surgical oncologists. These opinions are supported by outcomes data. In the previously quoted metaanalysis of systemic therapy in STS, 6 the hazard ratio with adjuvant chemotherapy for local recurrence was 0.73 (95% CI, 0.56-0.95), which corresponds to a 4% reduction in absolute risk. For synovial sarcoma, orthopedic oncologists felt most strongly about recommending chemotherapy, which may be explained by practice patterns (ie, orthopedic oncologists treat a higher proportion of younger patients with bone sarcoma and STS for whom chemotherapy is more routinely administered). For clinical scenarios in which adjuvant treatment is clearly indicated, such as radiation therapy for large or highgrade STS and chemotherapy for younger patients with favorable subtypes, any lack of agreement by specialists is concerning. Either the current data are felt to be inadequate to inform clinical decision making or there is unfamiliarity with data outside one's scope of practice. An argument could also be made for better quality studies. Furthermore, if the first point of contact for a patient is a specialist who places less importance on adjuvant therapy, then the treatment algorithm may not progress beyond surgical resection. Our data also point to the importance of a multidisciplinary STS tumor board. Even though individual physicians may have differing opinions about treatment, in aggregate, the best course for the patient will be charted by discussion and consideration of all treatment options. Finally, experience as measured by the percentage of clinical practice devoted to sarcoma care may also influence responses. In particular, physicians who had greater than 75% of their clinical practice devoted to sarcoma care placed more importance on systemic chemotherapy and a potential survival benefit with treatment. They were also more likely to recommend systemic chemotherapy for patients younger than 50 years of age and for tumors larger than 10 cm.
Certain limitations of our study must be acknowledged. Some are related to the survey methods that we used to collect our data. The use of a survey instrument has the inherent limitation of respondent bias because only physicians who were interested or inclined to respond took the time to do so. Although electronic dissemination results in easy and rapid delivery, many e-mail addresses were not valid or had filters, which meant that the survey never arrived to the intended recipient. By opting to only include physicians who were active members of selected oncology societies with a selfdeclared interest in sarcoma care, we also potentially introduced a selection bias. It is likely that there are additional physicians who treat a substantial number of patients with STS in their clinical practice who were not solicited to participate or who did not participate in this survey. Finally, although statistically significant differences were seen in the mean response rates for many of the questions, whether these translate into meaningful clinical differences is not demonstrated by our data.
To conclude, physician specialty appears to influence recommendations for adjuvant radiation therapy and chemotherapy in STS of the extremities. This bias likely arises from divergent interpretations of published literature and perhaps from a lack of familiarity with data outside of one's clinical scope of practice. Multidisciplinary clinics and tumor boards may be an effective tool for discussion among different specialties to reach consensus decisions and to minimize variation due to specialty bias. However, the effect of specialty bias on multimodality treatment recommendations of expert panels and tumor boards warrants further study. Author Contributions: Drs Wasif and Canter had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. 
